新华医疗
(600587)
| 流通市值：93.98亿 | | | 总市值：94.34亿 |
| 流通股本：6.04亿 | | | 总股本：6.07亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,977,967,842.53 | 4,790,414,888.01 | 2,307,531,823.28 | 10,020,618,625.09 |
| 营业收入 | 6,977,967,842.53 | 4,790,414,888.01 | 2,307,531,823.28 | 10,020,618,625.09 |
| 二、营业总成本 | 6,517,556,689.17 | 4,397,550,992.73 | 2,149,307,245.87 | 9,224,340,970.06 |
| 营业成本 | 5,225,989,859.88 | 3,582,676,003.81 | 1,758,644,239.58 | 7,409,687,368.01 |
| 税金及附加 | 49,294,464.71 | 33,170,450.39 | 14,799,018.49 | 68,778,820.95 |
| 销售费用 | 627,531,352.26 | 387,744,638.85 | 191,574,663.62 | 868,611,725.72 |
| 管理费用 | 271,695,712.22 | 178,062,225.44 | 84,486,138.45 | 422,075,778.52 |
| 研发费用 | 321,747,889.75 | 201,713,769.93 | 93,857,263.18 | 436,083,724.78 |
| 财务费用 | 21,297,410.35 | 14,183,904.31 | 5,945,922.55 | 19,103,552.08 |
| 其中:利息费用 | 31,806,317.28 | 21,348,494.52 | 10,844,514.18 | 44,793,595.87 |
| 其中:利息收入 | 14,415,796.3 | -9,225,075.47 | 5,063,781.89 | 24,744,881.82 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 48,281,980.32 | 52,113,996.21 | 11,590,440.94 | 70,823,343.99 |
| 资产处置收益 | -894,616.82 | -837,997.31 | -926,811.97 | 598,273.43 |
| 资产减值损失(新) | -29,650,386.99 | -14,253,517.71 | 2,504,021.98 | -70,302,431.87 |
| 信用减值损失(新) | -10,999,083.71 | -11,340,053.6 | -2,168,131.48 | -84,244,609.03 |
| 其他收益 | 51,200,205.94 | 36,093,544.73 | 21,026,349.59 | 85,364,820.68 |
| 四、营业利润 | 518,349,252.1 | 454,639,867.6 | 190,250,446.47 | 798,517,052.23 |
| 加:营业外收入 | 4,374,699.97 | 2,699,995.21 | 688,877.89 | 9,728,381.99 |
| 减:营业外支出 | 4,268,154.53 | 2,862,993.27 | 970,574.69 | 12,584,131.6 |
| 五、利润总额 | 518,455,797.54 | 454,476,869.54 | 189,968,749.67 | 795,661,302.62 |
| 减:所得税费用 | 74,371,769.85 | 64,085,293.87 | 28,741,160.67 | 103,764,322.5 |
| 六、净利润 | 444,084,027.69 | 390,391,575.67 | 161,227,589 | 691,896,980.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 444,084,027.69 | 390,391,575.67 | 161,227,589 | 691,896,980.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 434,310,536.42 | 385,717,607.04 | 160,455,800.07 | 691,609,558.03 |
| 少数股东损益 | 9,773,491.27 | 4,673,968.63 | 771,788.93 | 287,422.09 |
| 扣除非经常损益后的净利润 | 370,403,619.54 | 332,742,127.52 | 157,702,901.57 | 623,195,651.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.72 | 0.64 | 0.27 | 1.14 |
| (二)稀释每股收益 | 0.72 | 0.64 | 0.27 | 1.14 |
| 八、其他综合收益 | -10,798,668.15 | -3,094,830.46 | - | 3,526,890.99 |
| 归属于母公司股东的其他综合收益 | -10,798,668.15 | -3,094,830.46 | - | 3,526,890.99 |
| 九、综合收益总额 | 433,285,359.54 | 387,296,745.21 | 161,227,589 | 695,423,871.11 |
| 归属于母公司股东的综合收益总额 | 423,511,868.27 | 382,622,776.58 | 160,455,800.07 | 695,136,449.02 |
| 归属于少数股东的综合收益总额 | 9,773,491.27 | 4,673,968.63 | 771,788.93 | 287,422.09 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |